Integration of a virtual personalized medicine review board integration into a major community oncology phase 1 unit.

Abstract

11098 Background: Inclusion criteria for participating in oncology clinical trials have grown more complex, often challenging the enrollment process. Our objective was to improve the process of identifying and enrolling patients by incorporating personalized medicine assistance into the initial patient intake and trial selection procedure at a major community-based phase 1 oncology unit. Methods: A virtual personalized medicine review board (vPMRB) comprised of two PhD scientists reviewed patients for suitable trial options based on molecular sequencing results and scientific rationale during the intake and screening processes at a phase I oncology clinic. vPMRB reviews leveraged a propriety clinical trial identification software, Genospace, to generate patient-trial matches based on general inclusion/exclusion criteria including disease, histology, staging, and biomarker criteria. Trial options were returned via email and added to patients’ charts in the electronic health record for reference by their clinical care team. Trial candidates were screened for trial options and consented for treatment on trial by the enrollment nursing (ERN) team. Data pertaining to vPMRB review, trial screening, trial consent, and trial enrollment were collected by the vPMRB and ERN teams and combined to determine consent and enrollment rates. Results: Between 1/1/2024 and 12/31/2024, 953 patient reviews for 815 unique patients were completed by the vPMRB with an average turnaround time of 4 ± 5 business hours. 900 (94%) of these reviews included potential trial options for the patient. Of 790 reviewed patients with sufficient information for comparison with enrollment team data, 473 (60%) were screened for trial options by the ERN team in 2024. Of these, 343 (73%) consented to a trial and 270 (57%) started trial treatment in 2024. Comparatively, of the 744 patients reviewed for trial options by the ERN team, but not the vPMRB, 431 (58%) were consented to a trial and 313 (42%) started trial treatment in 2024. 167 (35%) patients consented to a trial and 130 (28%) patients started a trial recommended by the vPMRB for that patient in 2024. Conclusions: vPMRB review was associated with increased trial enrollment compared to patients without vPMRB review. Upcoming research will explore the effects of further personalized medicine integration techniques, including the involvement of team members in therapeutic strategy meetings held by clinical care teams, along with the use and effectiveness of clinical trial matching software in a phase 1 unit. Trial consenting and screening rates in 2024 for patients with and without vPMRB review. vPMRB Review No vPMRB Review Patients screened for trial by enrollment team 473 744 Consented on Trial 343 (73%) 431 (58%) Started Trial 270 (57%) 313 (42%) Consented on trial surfaced in vPMB review 167 (35%) N/A Started on trial surfaced in vPMB review 130 (28%) N/A